share_log

サンバイオ---大幅に反発、再生医療等製品の製造販売承認に期待、薬事審議会で部会開催へ

SanBio - Significantly rebounded, expecting approval for manufacturing and sales of regenerative medicine products, subcommittee to be held at the Pharmaceutical Affairs Council.

Fisco Japan ·  Jun 19 00:31

$SanBio (4592.JP)$Significantly rebounded. The Ministry of Health, Labour and Welfare's holding of the Regenerative Medicine and Bioengineering Subcommittee from 6 p.m. on the 19th is becoming a buying clue. SanBio's development product SB623 is included as an agenda item, stating the approval of manufacturing and sales, conditions and deadlines, and the need for re-examination period. It seems that there is an expectation that manufacturing and sales will be approved at the same subcommittee, making buying advantageous.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment